Research and Development

A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …

Amgen is set to pay $1 billion for US biotech firm BioVex, in the process gaining access to its novel …

GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …

Novartis has offered $470 million for a California-based laboratory whose diagnostic services it hopes will enhance personalised treatment. Genoptix specialises …

PPD sets up a monoclonal antibody JV in Singapore, plus updates from Icon plc, Cenix Bioscience, Clinipace Worldwide, Pacific Biomarkers, …

Edward Rowland has joined Wales-based pharmaceutical drug developer and manufacturer Penn Pharma as head of operational analytical services. He moves …

A promising Roche drug has helped previously untreated patients with advanced skin cancer to live longer without their disease getting …

The former head of the EMA Thomas Lönngren has taken up a post at new European regulatory and market access …

Sanofi-Aventis could be willing to raise its offer to $76 a share to buy the US biotech firm Genzyme, according …

A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …

Oxford, UK-based biotechnology company Syntaxin has appointed Dr Russell Greig as its new chairman.Russell has over 30 years experience in …

 

Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …

An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …

Merck & Co has enlisted the aid of contract research organisation Parexel to help it develop biosimilar versions of some …